Curon Biopharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Curon Biopharmaceutical Limited
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
- Other Names / Subsidiaries
- Curon Biopharmaceutical Hong Kong Ltd